Quinacrine, a drug with antimalarial and anticancer activities that inhibits NF-κB and activates p53, has progressed into phase II clinical trials in cancer. To further elucidate its mechanism of action and identify pathways of drug resistance, we used an unbiased method for validation-based insertional mutagenesis to isolate a quinacrine-resistant cell line in which an inserted CMV promoter drives overexpression of the FER tyrosine kinase (FER). Overexpression of FER from a cDNA confers quinacrine resistance to several different types of cancer cell lines. We show that quinacrine kills cancer cells primarily by inhibiting the activation of NF-κB and that increased activation of NF-κB through FER overexpression mediates resistance. EGF activates NF-κB and stimulates phosphorylation of FER, EGF receptor (EGFR), and ERK p42/p44, and decreased expression of FER or inhibition of ERK phosphorylation inhibits the EGF-induced activation of NF-κB. FER binds to EGFR, and overexpression of FER in cells untreated with EGF increases this association, leading to increased phosphorylation of EGFR and ERK. We conclude that FER is on a pathway connecting EGFR to NF-κB activation and that this function is responsible for FER-dependent resistance to quinacrine.
Quinacrine, a drug with antimalarial and anticancer activities that inhibits NF-κB and activates p53, has progressed into phase II clinical trials in cancer. To further elucidate its mechanism of action and identify pathways of drug resistance, we used an unbiased method for validation-based insertional mutagenesis to isolate a quinacrine-resistant cell line in which an inserted CMV promoter drives overexpression of the FER tyrosine kinase (FER). Overexpression of FER from a cDNA confers quinacrine resistance to several different types of cancer cell lines. We show that quinacrine kills cancer cells primarily by inhibiting the activation of NF-κB and that increased activation of NF-κB through FER overexpression mediates resistance. EGF activates NF-κB and stimulates phosphorylation of FER, EGF receptor (EGFR), and ERK p42/p44, and decreased expression of FER or inhibition of ERK phosphorylation inhibits the EGF-induced activation of NF-κB. FER binds to EGFR, and overexpression of FER in cells untreated with EGF increases this association, leading to increased phosphorylation of EGFR and ERK. We conclude that FER is on a pathway connecting EGFR to NF-κB activation and that this function is responsible for FER-dependent resistance to quinacrine. Q uinacrine has been used in humans for many years to treat malaria, autoimmune disorders, and other conditions (1) (2) (3) . Quinacrine simultaneously activates p53 and inhibits activated NF-κB, making it a very promising anticancer drug (4, 5) . To further elucidate its mechanism of action as an anticancer agent and identify pathways of resistance, we used validation-based insertional mutagenesis (VBIM) to generate mutant cells that resist killing by quinacrine. In VBIM, the strong CMV promoter is inserted into many different loci in the genomes of a population of mammalian cells, causing increased expression of downstream genes (6) . The inserted promoter can be excised to prove that the altered phenotype has been caused by the insertion. As a powerful tool for genetic study, VBIM has recently been applied to different selections, with productive outcomes (6, 7) .
NF-κB is activated by numerous external stimuli and has a major role in inducing inflammation. The canonical NF-κB complex of p65 and p50 subunits is sequestered in the cytoplasm through its association with the inhibitory subunit IκB (8) . After stimulation with cytokines such as TNFα or IL-1, IκB kinase (IKK) is activated, which leads to the phosphorylation of IκB, targeting it for proteosome-mediated degradation and liberating NF-κB (8) . Activated EGF also drives NF-κB activation, but the details of this pathway are not yet well-understood (9) (10) (11) . The binding of EGF to its receptor (EGFR), a receptor tyrosine kinase, leads to EGFR dimerization and autophosphorylation, and then, it leads to activation of downstream signaling pathways (12) . FER, a tyrosine kinase that is activated by cell-surface receptors such as EGFR, platelet-derived growth factor receptor (PDGFR), and FcγR after ligand engagement (13) (14) (15) , has an Nterminal FER-CIP4 homology (FCH) domain, three coiled coils, a central SH2 domain, and a carboxyl-terminal kinase domain (16) . Activated FER associates with and activates cellular proteins containing SH2 domains (17) (18) (19) (20) . We have now found that FER is on a pathway through which EGF activates NF-κB and that overexpression of FER activates NF-κB, thus conferring resistance to the NF-κB inhibitor quinacrine.
Results
Identification of FER in a Quinacrine-Resistant Clone. Eighteen different pools of human colon cancer RKO cells were infected with three different VBIM viruses (6) using a total of 1 million cells. After propagation, each pool was replated and treated with 10 μM quinacrine for 48 h. Twenty quinacrine-resistant colonies were observed 2 wk later in seven of the pools. The VBIM vectors contain LoxP sites, allowing excision of the promoter in candidate mutant clones. We infected each clone with a vector expressing Cre recombinase (6) followed by treatment with 10 μM quinacrine for 48 h. The quinacrine-resistant phenotype was reversed in mutant SD2-1 (Fig. 1A) , showing that the inserted CMV promoter caused the resistance in this case. We used two-step inverse PCR (iPCR) to identify the sequences flanking the insertion site in mutant SD2-1 (Materials and Methods). Two iPCR products were cloned and sequenced (Fig. 1B) . The sequences flanking one product are located on human chromosome 5q21 in intron 10 of the FER gene. The sequences flanking the other PCR product did not match any sequence in the database. The full coding sequence of FER translates to 822 aa, and the insertion leads to the expression of a truncated protein (TFER) with 356 aa, which still includes the complete SH2 and kinase domains. An analysis of mRNA revealed that TFER is expressed in mutant SD2-1 cells (Fig. 1C) , and a Western analysis showed the expression of TFER protein in these cells (Fig. 1D ). We expressed FER or TFER in unmutagenized colon cancer RKO cells or lung cancer H1299 cells ( Fig. 2 A and C) and tested their sensitivity to quinacrine. Overexpression of either protein confers resistance to both cell types ( Fig. 2 B and D) . The results in H1299 cells, which lack expression of p53 (1), show that the ability of FER to mediate quinacrine resistance does not depend on p53.
Up-Regulation of NF-κB Activity in Cells Overexpressing FER. NF-κB activation is a common mechanism through which tumors develop resistance to chemotherapy (21) , and one of the primary activities of quinacrine is to inhibit the constitutive activation of NF-κB (1, 22) . Therefore, we investigated the role of FER in regulating NF-κB activation in tumor cells. H1299 cells with an integrated NF-κB-dependent luciferase reporter (H1299#11 cells) were transduced with a vector expressing FER to create H1299FER#11 cells. In these cells, the overexpression of FER increased basal NF-κB-dependent luciferase activity (Fig. 3A) . When parental cells or cells overexpressing FER were treated with quinacrine, this activity was decreased (Fig. 3A) .
NF-κB Is Essential for Cancer Cell Survival. NF-κB is activated constitutively in many types of tumors (23) , inducing the expression of NF-κB-dependent genes whose products inhibit apoptosis and promote proliferation, inflammation, and invasion (24) . To show in the RKO colon cancer cells and H1299 lung cancer cells that we have studied that the constitutive activation of NF-κB is essential for survival, these cells were infected with a viral vector encoding an shRNA against the p65 subunit of NF-κB. Loss of p65 expression led to the death of both types of cells (Fig. 3B) . p65 knockdown also decreased the phosphorylation of p65 on Ser536 and expression of the p65 target gene intercellular adhesion molecule 1 (ICAM-1) (25) in both cell types (Fig. 3C) . Similar results were reported previously by Gurova et al. (4) .
Overexpression of FER Does Not Activate the AKT Pathway. It has been reported that the overexpression of FER increases the association of insulin receptor substrate-1 with the p85 subunit of PI3K (19) . Stimulation with PDGF also results in the formation of a complex between FER, PDGFR, and p85 (20) . Because activation of the PI3K/AKT pathway is known to activate NF-κB (26), we tested whether FER mediates NF-κB activation through this pathway. H1299 and H1299FER cells were treated with quinacrine, and AKT activity was analyzed in an in vitro kinase assay using the AKT substrate glycogen synthase kinase (GSK). Overexpression of FER did not affect AKT activity, and quinacrine treatment decreased AKT activity to the same extent in H1299 and H1299FER cells (Fig. 4A) . Also, FER overexpression did not increase the phosphorylation of AKT (Fig. 4B ). These results show that FER does not activate the PI3K/AKT pathway. Therefore, some other mechanism is responsible for the activation of NF-κB in response to FER overexpression.
FER and EGF-Dependent Signaling. Treatment of cells with EGF and PDGF stimulates FER phosphorylation (13, 14) . Treatment with EGF can also activate NF-κB (27, 28) , and several lines of evidence indicate that aberrant EGFR activation correlates with constitutively active NF-κB in cancer. In breast cancer cell lines, NF-κB activation has been shown to be downstream of EGFRdependent signaling, especially in estrogen receptor (ER)-negative cells (9, 10) . In prostate cancer cells, EGFR has been reported to regulate the constitutive activation of NF-κB (11) . To determine whether FER is involved in the activation of NF-κB in EGF-treated cells, we analyzed the effect of FER on the tyrosine phosphorylation of EGFR, finding that FER overexpression greatly increases EGFR phosphorylation (Fig. 4B ). Because the activation of ERK is a major downstream response to EGF and because the kinase activity of FER sustains ERK activation (29), we analyzed the phosphorylation status of ERK after FER overexpression. ERK phosphorylation was increased by FER overexpression, but the level of ERK protein did not change (Fig. 4B) . Phosphorylation of the p65 subunit of NF-κB on Ser536 contributes importantly to the transactivation of NF-κB in response to cytokines (30) , but overexpression of FER did not affect the phosphorylation of this residue, suggesting that FER does not activate NF-κB through this pathway (Fig. 4B ). To test whether EGFR and FER bind to each other constitutively, EGFR was immunoprecipitated from extracts of untreated H1299 or H1299FER cells and analyzed by the Western method. FER was associated with EGFR in H1299 cells, and there was more association in H1299FER cells (Fig. 4 C and D) . These results indicate that FER overexpression increases its association with EGFR and activates EGFR, even without EGF treatment.
We also tested whether EGFR is needed for FER to activate NF-κB. H1299#11 and H1299FER#11 cells were infected with a control shRNA or an shRNA against EGFR, and NF-κB activity was measured (Fig. 4 E and F) . Knockdown of EGFR decreased NF-κB activity in cells overexpressing FER but not in control H1299 cells. In SW620 cells, a colon cancer cell line that lacks EGFR expression (31) , FER overexpression activates NF-κB activity only slightly (Fig. 4 G and H) . These results suggest that EGFR plays a major role in the activation of NF-κB in response to FER overexpression. We then analyzed the kinetics of EGF-dependent activation of EGFR, FER, and NF-κB. Treatment of H1299#11 and H1299FER#11 cells with EGF led to NF-κB activation in a time-dependent manner ( Fig. 5 A and B) . The results shown in Fig. 5B indicate that FER overexpression greatly potentiates the ability of EGF to activate NF-κB. To monitor EGFR and FER activation, we measured the tyrosine phosphorylation of these proteins. H1299 cells were treated with EGF, cell lysates were immunoprecipitated with an antibody against phosphorylated tyrosine, and the immunocomplexes were analyzed by the Western method. Tyrosine phosphorylation of EGFR was apparent 1 min after treatment, but tyrosine phosphorylation of FER was not seen until 3 min (Fig. 5C ). As expected, treatment with EGF also increased the phosphorylation of AKT and ERK p42/44 (Fig. 5D) . We also examined how the canonical NF-κB pathway responds to EGF stimulation. There was no significant change in the phosphorylation of IKKα/β on Ser176/180, the phosphorylation of IκB on Ser32/36, or the phosphorylation of p65 on Ser536 (Fig. 5D ). We did detect decreased expression of IκB at late times, suggesting that EGF-induced activation of NF-κB might involve eventual degradation of IκB that is not mediated through the phosphorylation of Ser32 and Ser36 (Fig. 5D) . To test the role of FER in the EGF-mediated activation of NF-κB more directly, the expression of FER was inhibited by shRNA in H1299#11 cells (Fig. 5E ) followed by stimulation with EGF. EGF increased NF-κB-dependent activity in a dose-dependent manner in control cells, but when FER expression was knocked down, the cells did not activate NF-κB activity as well (Fig. 5F ), confirming that FER is involved in EGF-dependent NF-κB activation. Pretreatment with EGF also prevented quinacrinemediated inhibition of NF-κB slightly (Fig. S1) but not enough to protect the cells from quinacrine-mediated cell death (Fig. S2) . Because ERK is activated either by FER overexpression or EGF stimulation, we tested the effect of inhibiting ERK on EGF-induced NF-κB activation in H1299#11 and H1299FER #11 cells. Pretreatment with an ERK inhibitor reduced EGFinduced activation of NF-κB in both cells, but the inhibition of NF-κB is much more profound in H1299FER#11 than H1299 cells (Fig. 6 A and B) .
Discussion
Development of drug resistance is a major problem in cancer treatment, and it is almost universally the case that treatment with a single drug leads to resistance (32) . Resistance can occur through several different mechanisms, including amplification or mutation of a target gene and increased expression of proteins that transport the drug out of treated cells (32, 33) . In the VBIM method, introduction of a CMV promoter can induce the overexpression of downstream genes, and if increased expression of the corresponding protein facilitates survival, the cells will be resistant to the drug. Previously, we used VBIM to show that the overexpression of kinesins mediates resistance to docetaxel (7), and here, we use this method to isolate a quinacrine-resistant clone with an insertion in the FER gene (Fig. 1B) . We then confirm that FER overexpression confers resistance to quinacrine in naïve cells without mutagenesis (Fig. 2 B and D) .
FER is expressed ubiquitously in a variety of tissues and cells (16) and is expressed at a higher level in numerous malignant cell lines than the corresponding normal cells (34) (35) (36) . FER expression has been linked to prostate cancer, with higher levels in extracts from cancers compared with normal or hyperplasic tissues (34, 35) . Overexpression of Drosophila FER caused malignant transformation of rodent fibroblasts (37) .
Here, we show that FER overexpression activates NF-κB (Fig. 3A) , helping to explain its oncogenic properties. Constitutive activation of NF-κB, apparent in most tumors, activates genes whose products are essential for cancer cell survival and proliferation, and many tumors cannot tolerate inhibition of activated NF-κB. We have also shown that knockdown of the p65 subunit of NF-κB kills different lines of cancer cells (Fig. 3  B and C) , showing that NF-κB expression is necessary for their survival.
EGF plays an important role in cell proliferation and survival by activating downstream of signaling pathways involving PI3K/ AKT and ERK (38) . Ligand binding to EGFR leads to receptor dimerization, autophosphorylation, and activation of downstream pathways. Mutant EGFRs exhibit ligand-independent dimerization and activation of downstream signaling pathways (38) . We show here that EGFR binds to FER and that this binding is increased in H1299FER cells (Fig. 4C) .
We have also found that overexpression of FER increases the tyrosine phosphorylation of EGFR, the phosphorylation of ERK, and the activation of NF-κB, even in the absence of EGF (Fig.  4B) . Although AKT is a downstream target of EGF-dependent signaling, we did not see AKT activation in response to FER overexpression (Fig. 4A) , indicating that AKT is not involved in the FER-mediated activation of NF-κB. Consistent with this result, overexpression of HER2, an EGFR family member, also did not activate NF-κB through the AKT pathway (39) .
Treatment with EGF stimulated rapid and dramatic activation of EGFR and FER, which was revealed by tyrosine phosphorylation and activation of NF-κB. Because the tyrosine phosphorylation of EGFR is apparent as soon as 1 min after treatment and the dramatic tyrosine phosphorylation of FER is seen slightly later (after 3 min) (Fig. 5B) , we propose that FER may be activated by EGFR directly after binding of the SH2 domain of FER to one or more phosphotyrosine residues of EGFR after treatment with EGF. We also detected association of FER with EGFR even in the absence of treatment. FER overexpression increases its association with EGFR and activates EGFR (Fig.  4B ), indicating that FER and EGFR can activate each other. We also show that inhibition of ERK activity inhibits the ability of EGF to induce the activation of NF-κB (Fig. 6A) . All of these results indicate that FER is a component of an EGFR to NF-κB signaling pathway (Figs. 5D and 6 A and B) . Further work is required to reveal additional components of this pathway. Quinacrine is currently being evaluated as a therapeutic agent for several types of cancer (1, 5) . Our finding that activation of EGFR induces quinacrine resistance may indicate that quinacrine may be more effective in patients with normal levels of EGFR and FER than in patients with overexpression of these proteins. It may also be advantageous to combine an ERK inhibitor with quinacrine for therapy.
Materials and Methods
Cells and Reagents. H1299, RKO, and 293T cells were obtained from ATCC. H1299, H1299#11, and 293T cells were maintained in DMEM supplemented with 5% heat-inactivated FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin. RKO cells were maintained in RPMI medium supplemented with 10% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin. All cultures were kept in 5% CO 2 at 37°C. Antibodies against FER, AKT, phospho-EGFR (Tyr1068), phospho-ERK (Thr202/Tyr204), ERK, phospho-AKT (Ser473), ICAM-1, phospho-IKKα/β (Ser176/180), and phospho-p65 (Ser536) were from Cell Signaling. Antibodies against p65, IκB, IKKα/β, phospho-IκB (Ser32/36), and GAPDH were from Santa Cruz Biotechnology. The antibody against EGFR was from Bethyl, and the antibody against phosphotyrosine was from BD Biosciences. The ERK inhibitor PD098059 was from EMD Chemicals.
Constructs, Virus Production, and Infection. Human or mouse FER cDNAs were used interchangeably. They gave very similar results when compared in parallel experiments. The cDNAs were subcloned in the p-CMV-SV-40-puro lentivector (40) . PLA-NF-κBLuc (41) was a gift from Peter Chumakov (Cleveland Clinic, Cleveland, OH). shRNAs against FER and p65 were from SigmaAldrich. To produce infectious virus, 293T cells were transfected transiently with pCMVDR8.2 and pVSV-G helper plasmids (5) as well as the plasmid of interest by using Lipofectamine Plus (Invitrogen). The virus produced was collected 24, 48, and 72 h after infection and concentrated using 40% polybrene followed by centrifugation at 2,800 × g for 20 min. To obtain stable populations, target cells were infected with virus and then selected for 2 wk.
Mapping the Inserts. Mutant cells were cultured to 80% confluency in p100 plates. Genomic DNA was isolated from the cells using the blood and cell culture DNA midi Kit from Qiagen, digested with EcoRI and MfeI, and self-ligated with DNA ligase. The ligation products were subjected to nested PCR (6, 7).
Cell Survival Assay. Cells were plated into 24-well plates at 30,000 cells/well. The next day, the cells were treated with quinacrine for 24 h and allowed to grow for another 24 h. Then, Cell Titer Blue (Promega) was added to the medium at a ratio of 1:5, the cells were incubated at 37°C for 1-4 h, and the fluorescence intensity was measured.
Immunoblotting and mRNA Expression. Cells were cultured to 80% confluency in six-well plates. After treatment, the cells were lysed with RIPA buffer (25 mM Tris·HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS) containing protease inhibitor mixture (Sigma-Aldrich) and Halt phosphatase inhibitor mixture (Thermo Scientific). The lysate was centrifuged at 11,000 × g for 20 min. The concentrations of proteins in the supernatant solutions were measured by using a protein assay kit (Bio-Rad). Protein samples (20 μg) were separated in NuPAGE 4-12% electrophoresis gels (Invitrogen) and transferred to polyvinylidene difluoride membranes; immunoblot was performed according to the guidelines for each specific antibody. To determine the mRNA expression levels, total cellular RNAs were extracted by using the RNeasy Mini Kit (Qiagen). The reverse transcription (RT) reaction was performed by using the SuperScript II First-Strand Synthesis system (Invitrogen), and PCR was done with TFER-specific primers.
Luciferase Reporter Assay. H1299#11 cells were infected with virus expressing FER or the corresponding control virus. Two days after infection, cells were replated in 12-well plates. The next day, the cells were treated with quinacrine (10 μM) overnight or EGF (100 ng/mL) for various times. After treatment, the cells were harvested in reporter lysis buffer (Promega). A 5-μL aliquot of the supernatant solution was assayed with the luciferase assay system (Promega) after brief centrifugation at 11,000 × g. The luciferase activity was normalized for protein concentration.
Immunoprecipitation. H1299 cells were cultured to 80% confluency in 10-cm plates and then treated with EGF (100 ng/mL). Cells were lysed with immunoprecipitation (IP) buffer (20 mM Tris·HCl, pH 8, 137 mM NaCl, 10% glycerol, 1% Nonidet p-40, 2 mM EDTA) containing protease inhibitor mixture (Sigma) and Halt phosphatase inhibitor mixture (Thermo Scientific). After agitation for 30 min, the cells were centrifuged at 11,000 × g for 20 min. Equivalent amounts of supernatant solutions were mixed with an antibody against phospho-tyrosine at 4°C overnight, with rotation. Immunocomplexes were precipitated with protein A/G agarose beads (Santa Cruz). The beads were washed four times with IP buffer, and the immunoprecipitates were analyzed by the Western method using specific antibodies.
AKT in Vitro Kinase Assay. The AKT in vitro kinase assay kit from Cell Signaling was used according to the manufacturer's protocol.
Statistical Analysis. Values were expressed as means ± SD. P values were based on the t test, and the significance was set at 0.05 (marked with an asterisk wherever data are statistically significant).
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